Trial reportLa Tunisie medicale2025
Prevention of bleeding in total hip and knee replacement: Contribution of combined route in tranexamic acid administration.
Trial report in La Tunisie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Definition, analysis, reporting, and interpretation of perioperative bleeding in randomized controlled trials: a methodological systematic review.Perioperative medicine (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTranexamic acid (TXA) has revolutionized perioperative blood management of total hip (THA) and knee arthroplasties (TKA). However, there is currently no consensus on the optimal administration route.
aimTo compare the combined administration of TXA (intravenously (IV) and topically) versus IV alone on the reduction of postoperative bleeding in THA and TKA.
methodsA nine-month double-blind randomized trial was conducted. Adult consenting patients scheduled for primary total hip arthroplasty (THA) or total knee arthroplasty (TKA) were included. The primary outcome measure was the decrease in hemoglobin levels 24 hours after surgery. They were randomized either to the IV group (51 patients) receiving 2 doses of 1 g of IV TXA 3 hours apart, or to the Combined group (50 patients) receiving 1 g of IV TXA and a topical dose of 1.5 g.
resultsThe mean decrease in hemoglobin 24 hours after surgery was similar for both groups in THA (p=0.91) and TKA (p=0.19). There was no difference in perioperative transfusion rate between the two THA groups (p=0.6). In TKA, no perioperative transfusion was required. Total and measured blood losses were similar in both groups. Immediate and 3-month postoperative complications were similar.
conclusionCompared to IV TXA alone, the combined route does not reduce the risk of bleeding in prosthetic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.